Bicara Therapeutics Inc. (BCAX)
BCAX moved a median of +0.21% 30 minutes after news, and -0.20% by the close. How BCAX actually reacts to news — the realized, point-in-time move the market made, measured across 239 labeled events over the last three years with zero look-ahead.
BCAX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.17% | 39% | 238 |
| 30-min | +0.21% | 53% | 239 |
| 60-min | -0.16% | 48% | 239 |
| to close | -0.20% | 48% | 237 |
| Middle 50% of BCAX reactions | -1.25% to +1.57% |
|---|---|
| Median reaction (30-min) | +0.21% |
| Measured reactions | 239 |
Half of all Bicara Therapeutics Inc. news events land between -1.25% and +1.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BCAX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.08% | 46% | -1.12% |
| Coverage initiations | 39 | +0.97% | 51% | -0.06% |
| Rating reiterations | 42 | +0.09% | 57% | +1.98% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how BCAX ranks against every other measured name →
That’s how BCAX usually reacts — get an email when it moves on news →Email me when BCAX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCAX's baseline. Nothing else.
Recent BCAX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -1.93% | |
| Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.67% | -1.60% | |
| Form 8-K Bicara Therapeutics Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | +0.81% | |
| Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.13% | +3.72% | |
| Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | Press release | GlobeNewswire | +11.54% | +4.21% | |
| Form 10-Q Bicara Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.06% | +2.63% | |
| Form 8-K Bicara Therapeutics Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +11.54% | +4.21% | |
| Form S-8 Bicara Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.06% | +2.63% | |
| Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | Press release | GlobeNewswire | +0.27% | -0.53% | |
| Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors | Press release | GlobeNewswire | -0.36% | -2.68% | |
| Form 8-K Bicara Therapeutics Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -2.68% | |
| Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.76% | -0.45% | |
| Form 8-K Bicara Therapeutics Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | +4.42% | |
| Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | Press release | GlobeNewswire | -0.92% | +4.03% | |
| Form 8-K Bicara Therapeutics Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | +4.03% | |
| Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.45% | -6.13% | |
| Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.33% | +1.91% | |
| Form 10-Q Bicara Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.02% | -2.40% | |
| Form 8-K Bicara Therapeutics Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | +1.91% | |
| Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET | Press release | GlobeNewswire | +0.42% | +5.04% | |
| Form ARS Bicara Therapeutics Inc. For: Apr 21 | SEC filing · Form ARS | SEC EDGAR | +1.11% | -0.29% | |
| Form DEF 14A Bicara Therapeutics Inc. For: Apr 21 | SEC filing · Form DEF | SEC EDGAR | +1.11% | -0.29% | |
| Form DEFA14A Bicara Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.11% | -0.29% | |
| Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -3.38% | |
| Form S-8 Bicara Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.08% | +2.47% | |
| Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.55% | +0.90% | |
| Form 10-K Bicara Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.08% | +2.47% | |
| Form 8-K Bicara Therapeutics Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -3.55% | +0.90% | |
| Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET | Press release | GlobeNewswire | -1.18% | -1.13% | |
| Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.50% | +3.46% | |
| Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.98% | -0.12% | |
| Form 8-K Bicara Therapeutics Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | -0.12% | |
| Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +0.84% | -2.02% | |
| Bicara Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +0.84% | -2.02% | |
| Bicara Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.78% | +6.08% | |
| Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen | Press release | GlobeNewswire | +1.69% | +0.58% | |
| Form 8-K Bicara Therapeutics Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | +0.58% | |
| Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.87% | -6.44% | |
| Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook | Press release | GlobeNewswire | -2.45% | -2.90% | |
| Form 8-K Bicara Therapeutics Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.45% | -2.90% | |
| Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 | Press release | GlobeNewswire | +0.78% | -1.82% | |
| Form 8-K Bicara Therapeutics Inc. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | +2.38% | |
| Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 | Press release | GlobeNewswire | +0.19% | +2.38% | |
| Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 | Press release | GlobeNewswire | +1.24% | -4.57% | |
| Form EFFECT Bicara Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.16% | -2.16% | |
| Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.38% | -5.75% | |
| Form 10-Q Bicara Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.40% | +6.74% | |
| Form 8-K Bicara Therapeutics Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | -5.75% | |
| Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology | Press release | PR Newswire | -0.49% | -1.73% | |
| Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC | Press release | GlobeNewswire | +2.00% | -0.22% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCAX section they belong to.
Where else BCAX is measured.
BCAX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Bicara Therapeutics Inc.'s median reaction calculated?
Every labeled BCAX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 239 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of BCAX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCAX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.